A frontier model can already enumerate 10,000+ candidate proteins or 106 small molecules in seconds. None of that becomes value until atoms move: DNA must be synthesized, cells must express, assays must run, bioreactors must ferment, GMP manufacturing must release lots. The hard, slow, capital-intensive parts of this stack — long-read sequencing, oligo/gene synthesis, single-use bioprocessing, contract biomanufacturing, lab automation hardware — are the physical compiler for AGI-designed biology. They are largely an oligopoly, were brutally re-priced in the 2022–2024 bear market, and are now mid-recovery while the cognitive layer above them goes vertical.
Isomorphic Labs' May 2026 $2.1B Series B (Thrive-led, Alphabet/CapitalG/GV) is the loudest market signal: the smartest AI lab in drug design wants to spend ten figures on outsourced wet-lab cycles. They need a working physical backend. Recursion, Schrödinger, Generate, Xaira, Iambic, and the OpenAI biology efforts all share this constraint. The picks-and-shovels names sitting between AI compute and clinical biology are the leveraged trade.
| Layer | Today's binding constraint | What AGI demand multiplies |
|---|---|---|
| DNA / gene synthesis | Twist ~$0.07/bp for short oligos, $0.10–0.30/bp for genes; multi-week lead times for libraries >10kb. Twist FY26 guide ~$445M revenue (small relative to demand). | Protein design at scale needs millions of synthesized constructs per project. Demand is supply-elastic. |
| Long-read sequencing | PacBio just shipped SPRQ-Nx: sub-$300 HiFi genome, ~30% lower cost. Still 3–5x Illumina short read for the same depth. PACB FY26 guide only $165–175M. | AI training data for genomics/structural variants is long-read native. PACB+ONT capacity is a floor. |
| Short-read sequencing | Illumina dominates installed base; competitive pressure from Element AVITI, Ultima UG100, MGI on $/Gb. ILMN raised FY26 guide to $4.52–4.62B. | Population-scale biobanks (UKBB, All-of-Us, China precision medicine) demand 10x throughput. Marginal capacity matters. |
| Lab automation hardware | Tecan TTM rev CHF 882M (down 5.5% YoY, net loss); Hamilton private; Beckman inside Danaher. Lead times 6–12 months for high-end liquid handlers. | Each AI-bio company building in-house automation (Recursion, Insitro, Xaira) buys here. |
| Single-use bioprocessing | Sartorius + Repligen + Cytiva (Danaher) + MilliporeSigma own ~80% of single-use bags, filters, chromatography resin. Lead times for protein A resin still 6+ months. | Every biologic, every cell therapy lot needs them. Demand grows with both AI-discovered biologics AND GLP-1 fill-finish. |
| CDMO biologics capacity | Lonza, Samsung Biologics, Fujifilm, WuXi Biologics committed >$3B in capacity expansion. Samsung Q1 2026 revenue KRW 1.257T (~$849M). Lonza Stein facility online 2026, Samsung Songdo to 360kL by 2030. | AGI-designed biologics still need GMP fermentation. Bookings are already 3–5 years out at top-tier shops. |
| Cloud / automated labs | Emerald Cloud Lab, Strateos, Arctoris are still small, private, capacity-constrained. ECL CMU partnership real, but throughput << what AI demand wants. | The most direct "cognition → experiments" pipe. Severely undersupplied. |
| Mass spec / proteomics | Bruker (timsTOF), Thermo (Orbitrap), Waters, Sciex (Danaher). Bruker TTM $3.46B; Waters $3.77B. Lead times stretching. | Protein-level validation of AI predictions = proteomics-heavy workflows. |
Rough mental model for 2026–2030:
| Input | 2026 baseline | 2030 demand (AGI-on) | Implied multiple |
|---|---|---|---|
| Synthetic genes shipped (bp/yr, industry) | ~1012 | 1014+ | 100x |
| Sequenced genomes/yr (industry) | ~5–10M | 100M+ (incl. cell-free dx, longitudinal) | 10–20x |
| Cloud-lab experiments/day (global) | 103–104 | 106+ | 100–1000x |
| Biologic GMP fermenter capacity (kL) | ~5,000 (global) | 15,000+ | 3x (capex+regulatory bound) |
| Lab automation install base ($) | ~$10B/yr cap | $30–50B/yr | 3–5x |
Estimates — my synthesis from industry reports, not company filings. Sequencing and synthesis numbers are first-principles "AI-bio will need this" estimates, not analyst consensus. Treat as order-of-magnitude.
| Ticker | Name | Mkt Cap (live) | TTM Rev | Mult. | Why bottleneck | Risks | Priced-in? |
|---|---|---|---|---|---|---|---|
| TWST | Twist Bioscience | $4.04B | $409M | 9.9x PS | Dominant gene-length DNA synthesis. Single biggest input to AI protein design at scale. FY26 guide $442–447M, +17% YoY, Q4 EBITDA breakeven. | Ansa enzymatic synthesis could disrupt 5+ yrs out. Stock already +107% YoY. | Partly |
| RGEN | Repligen | $6.50B | $763M | 8.5x PS / 127 PE | Protein A resin + filtration: the bottleneck input to every monoclonal antibody and biologic lot. Recovering: TTM rev +17.4%. | Expensive on earnings. Tied to biotech funding cycle. | Partly |
| SRT3.DE | Sartorius | €14.36B | €3.55B | ~4x PS / 88 PE | The European Repligen+Cytiva equivalent. Single-use bioreactor leader. Mid-term guide 8–11% organic growth. | P/E still pricey after the de-rate. Pharma capex slow to recover. | Partly |
| LONN.SW | Lonza | CHF 34.3B | CHF 6.53B | 5.3x PS | Largest Western biologics CDMO. Stein expansion online 2026. Booked years out. Plays the GLP-1/biologic capacity squeeze and the AI-designed-biologic future. | Currently unprofitable TTM (restructuring). Forward P/E 27 not cheap. | Partly |
| DHR | Danaher (Cytiva + Beckman + Sciex + IDT + Leica + Pall) | $122B | $24.8B | 5.0x PS / 33 PE | The conglomerate ETF for life sciences tools: Cytiva (bioprocess), IDT (oligos), Beckman (auto), Sciex (mass spec), Leica (microscopy). Owns 4 of the 8 layers above. | Mega-cap, modest growth. Diversification dilutes pure AI-bio leverage. | Cheap-ish |
| TMO | Thermo Fisher | $167B | $45.2B | 3.7x PS / 25 PE | The Walmart of bio tools + cryo-EM (FEI) + reagents + CRO (PPD). The default "buy the index" of bio infrastructure. | Hard for the elephant to dance — growth muted vs. focused names. | Reasonable |
| ILMN | Illumina | $22.0B | $4.39B | 5.0x PS / 26 PE | ~70% global short-read sequencing share. NovaSeq X drives $/Gb floor. FY26 guide raised. | Element, Ultima, MGI, Singular pressuring on price. Long-read share migrating to PACB/ONT. | Cheap |
| PACB | Pacific Biosciences | $391M | $160M | 2.5x PS | Long-read leader; SPRQ-Nx shipping sub-$300 HiFi genome. Trading near multi-year lows. | Tiny, unprofitable, capital constraints. ONT real competitor. | Cheap, optionality |
| SDGR | Schrödinger | $983M | $255M | 3.85x PS | Physics-based + AI molecular design. Software business is the only AI-bio infra public-market pure-play. 23% TTM revenue growth, narrowing losses. | Equity stakes in clinical programs add binary risk. Hasn't broken out commercially. | Cheap |
| BRKR | Bruker | $7.14B | $3.46B | 2.1x PS | Cryo-EM, mass spec, NanoString (spatial), Berkeley Lights (single-cell). Hardware moats in 3 separate biology-validation modalities. | Flat revenue YoY. Indigestion from acquisitions. | Cheap |
| WAT | Waters | $33.3B | $3.77B | 8.8x PS / 49 PE | LC-MS gold standard. AGI biology = orders of magnitude more validation chromatography. | Already richly priced. Slow growth. | Mostly |
| A | Agilent | $32.5B | $7.07B | 4.6x PS / 25 PE | Mass spec + LC + reagents + CRO services + diagnostics. Solid second-tier exposure. | Less pure-play than peers. Diversified across cyclical end markets. | Reasonable |
| RVTY | Revvity (ex-PerkinElmer) | $10.8B | $2.90B | 3.7x PS | Reagents + dx + automation. Post-divestiture of diagnostics-China, leaner. | Soft FY26 guide. Multiple downgrades. | Cheap |
| TECH | Bio-Techne | $7.51B | $1.21B | 6.2x PS / 69 PE | Specialty reagents (R&D Systems): the input to every academic AI-bio lab. | Pricey on PE. Flat top line. | Mostly |
| TXG | 10X Genomics | $3.13B | $639M | 4.9x PS | Single-cell + spatial. New Atera platform. Bounced hard off lows (+194% YoY mkt cap). | Competition from Bruker/NanoString. NIH funding overhang. | Partly |
| MRVI | Maravai LifeSciences | $1.13B | $205M | 5.5x PS | TriLink (CleanCap, modified nucleotides): the unsung input to every mRNA therapeutic and now AI-designed gene therapy. Q1 +41% YoY. | Volatile, post-COVID hangover. Highly sensitive to mRNA cycle. | Cheap on recovery |
| TECN.SW | Tecan | CHF 1.87B | CHF 882M | 2.1x PS | Liquid handling robots: the substrate of automated biology. Trading at 5-yr lows after revenue dip. | Currently unprofitable. Demand soft, but cyclical floor. | Cheap |
| RXRX | Recursion Pharmaceuticals | $1.58B | $66M | 24x PS | In-house automated wet lab (Salt Lake). Owns the closest US analog to a cloud lab. NVIDIA partnership real. | Drug pipeline mostly preclinical; burning $645M/yr. Stock at all-time lows. Hold-rated. | Bombed-out |
| ABSI | Absci | $823M | $1.8M | 447x PS (lol) | AI antibody design + in-house wet lab. ABS-201 in P1/2a. | Effectively a biotech, not infrastructure. Don't size as infra. | Binary |
Multiples: PS = price/sales (TTM), PE = price/earnings. Live data as of 2026-05-26 close from stockanalysis.com.
Closest thing to "the TSMC of biology." Effectively monopoly economics on silicon-based oligo + gene synthesis at the volumes AI biology needs. FY26 guide $442–447M, +17% YoY, Q4 EBITDA breakeven means the unit-economics fight is largely won. Up 107% YoY but at 9.9x PS still light-years cheaper than any software AI proxy. If Isomorphic, Xaira, Recursion all 10x their experimental throughput, this is one of two suppliers in the world (Twist + IDT-inside-Danaher).
What I would pay for: Demonstrated Q4 adj-EBITDA breakeven, then size up. Already a buy here.
The bioprocess consumables duopoly. Every biologic, every cell therapy, every AI-designed drug substance flows through their bags, filters, and resins. Both got crushed 70% from 2021 highs and are 18–24 months into recovery. Sartorius mid-term guide 8–11% organic. RGEN TTM rev +17%. The PE looks optically expensive because earnings are emerging from a trough — this is exactly the wrong way to value an operating-leverage recovery.
What I would pay for: Sartorius is more capacity-leveraged (broader portfolio); Repligen is more direct mAb-exposure. Own both.
The unfair ETF: Cytiva + IDT + Beckman + Sciex + Pall + Leica + Aldevron inside one ticker. 4 of the 8 bottleneck layers above are inside DHR. At 5x PS / 33 PE for a $122B compounder with multiple monopoly-positioned subsidiaries, the risk/return is exceptional for "I want exposure but don't want to pick the right small-cap." Use as core; complement with the focused names.
What I would pay for: Already reasonably priced. Buy a starter, add on any pharma-capex scare.
The only public-market pure-play on AI-bio software/infrastructure that isn't either a biotech-with-a-pipeline or a tools conglomerate. 23% TTM rev growth, $983M mkt cap, 3.85x PS. Stock fell 44% YoY on weak biotech end-market spend and pipeline timing — but the platform is the long-term asset. Their FEP+ AI hybrid is what Isomorphic and Xaira would use if they didn't roll their own. Best risk/reward in the software-of-biology bucket below $15.
What I would pay for: Conviction grows materially if they win a major Big Pharma platform deal or one of their equity-stake pipeline assets hits.
Best Western CDMO. Capacity coming online into structural shortage (mAbs + ADCs + cell therapy + AI-designed biologics + GLP-1 secondary fill). Books years out. Currently unprofitable on restructuring, which is exactly when quality CDMOs should be bought. Geopolitical kicker: every dollar that gets pulled from WuXi by US BIOSECURE-style action lands at Samsung or Lonza.
What I would pay for: Forward P/E 27 isn't dirt cheap but it's a quality compounder at a trough margin. Size patiently.
All live price/market cap data: stockanalysis.com market close 2026-05-26.
Document generated 2026-05-26. All forward-looking quantitative ratios (supply/demand model, $/bp, $/genome at scale) are analyst estimates and should be treated as order-of-magnitude. Live financial data is from public market sources at market close.